Last reviewed · How we verify
Concerta AG formulation
Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor.
Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor. Used for Attention Deficit Hyperactivity Disorder (ADHD).
At a glance
| Generic name | Concerta AG formulation |
|---|---|
| Also known as | Methylphenidate |
| Sponsor | Janssen Research & Development, LLC |
| Drug class | Central Nervous System Stimulant |
| Target | Norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Methylphenidate increases the levels of norepinephrine and dopamine in the brain by preventing their reuptake, which improves attention and impulse control.
Approved indications
- Attention Deficit Hyperactivity Disorder (ADHD)
Common side effects
- Insomnia
- Headache
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Concerta (Methylphenidate) -To-Generic Switch Study
- Methylphenidate (Ritalin®) Effect During Exposure to Exercise and Heat Stress in ADD/ADHD Treated Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |